Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 20/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4465836 | 0.88 | HRH3 (1.00) | HRH3KCNH2ADRA1A | |
| SCHEMBL3944761 | 0.88 | HRH3 (1.00) | HRH3KCNH2ADRA1A | |
| SCHEMBL4464124 | 0.88 | HRH3 (1.00) | HRH3KCNH2ADRA1A | |
| SCHEMBL4462569 | 0.86 | HRH3 (0.77) | HRH3KCNH2ADRA1A | |
| SCHEMBL502317 | 0.85 | HRH3 (0.79) | HRH3KCNH2ADRA1A | |
| SCHEMBL4463080 | 0.85 | HRH3 (1.00) | HRH3KCNH2ADRA1A | |
| SCHEMBL4478270 | 0.85 | HRH3 (0.75) | HRH3KCNH2 | |
| Hydrochloric Acid SCHEMBL4471965 | 0.85 | HRH3 (0.78) | HRH3KCNH2ADRA1A | |
| SCHEMBL4474003 | 0.84 | HRH3 (0.76) | HRH3KCNH2ADRA1A | |
| SCHEMBL502438 | 0.84 | HRH3 (0.79) | HRH3KCNH2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1717230-B1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-8268842-B2 | Fused ring 4-oxopyrimidine derivative | MSD K.K. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-7521455-B2 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | HRH3 3/4885KCNH2 299/4885ADRA1A 100/4885 |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | HRH3 3/4885KCNH2 299/4885ADRA1A 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.